The Evolution of Prognostic Factors in Multiple Myeloma
Open Access
- 21 February 2017
- journal article
- review article
- Published by Hindawi Limited in Advances in Hematology
- Vol. 2017, 1-11
- https://doi.org/10.1155/2017/4812637
Abstract
Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the disease remains incurable. All efforts are currently focused on understanding the prognostic markers of the disease hoping to incorporate the new therapeutic modalities to convert the disease into curable one. We present this comprehensive review to summarize the current standard prognostic markers used in MM along with novel techniques that are still in development and highlight their implications in current clinical practice.Keywords
This publication has 103 references indexed in Scilit:
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia, 2012
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesBlood Cancer Journal, 2012
- Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myelomaExperimental Hematology & Oncology, 2012
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBlood, 2010
- Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplantLeukemia, 2009
- An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaBlood, 2008
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008
- Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998